Luspatercept  (Synonyms: ACE-536; luspatercept–aamt)

Luspatercept (ACE-536) is a recombinant modified ActRIIB fusion protein that binds with transforming growth factor β superfamily ligands. Luspatercept increases the erythrocyte numbers and promotes maturation of erythroid precursors. Luspatercept binds with GDF11 and inhibits Smad2/3 signaling. Luspatercept can be used for the research of anemia^[1].

Human

Luspatercept (0.1-1000 ng/mL) inhibits Smad2 and Smad 3 signaling induced by GDF11 and GDF8 in A204 cells^[1].
Luspatercept binds with GDF11, GDF8, activin B, BMP10 and BMP6^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Luspatercept (0.1-60 mg/kg, s.c.; 10 mg/kg, i.v.; twice weekly for 8 weeks) increases red blood cell (RBC) count, hemoglobin levels and hematocrit in mice, rats and monkeys^[1].
Luspatercept (10 mg/kg; s.c., once) reduces erythroid burst forming units (BFU-Es) and erythroid colony-forming units (CFU-Es) from bone marrow and spleen of C57BL/6 mice^[1].
Luspatercept (10 mg/kg; i.p., once) inhibits Smad2/3 phosphorylation in mouse spleen^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

1373715-00-4

Liquid

Colorless to light yellow

[Luspatercept]

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  [ACVR2B (activin A receptor type 2B, ActR-IIB, ActRIIB)]2-IGHG1 Fc (Fragment constant)

• 
  Immobilized Recombinant Anti-ACVR2B Antibody can bind Luspatercept. The EC₅₀ for this effect is 3.08 ng/mL.

• [1]. Suragani RN, et al. Transforming growth factor-β superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis. Nat Med. 2014 Apr;20(4):408-14.  [Content Brief]